8x8 Inc vs Revolution Medicines Inc. Common Stock — how do they compare? 8x8 Inc trades at $2.1 (market cap $311.98M), while Revolution Medicines Inc. Common Stock trades at $189.76 (market cap $40.32B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 129.2× 8x8 Inc's market cap, and Revolution Medicines Inc. Common Stock is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| EGHT | RVMD | |
|---|---|---|
Market Cap | $311.98M | $40.32B |
Volume | 1,639,086 | 4,855,734 |
Sector | Technology | Health |
52-Week High | $2.76 | $221.15 |
52-Week Low | $1.59 | $47.50 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $578.90M | $37.02B |
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.11, down 1.4% today, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights cost-saving client wins and AI product growth, while analysts maintain a mixed consensus with a $19.77 price target representing significant upside potential.
The stock presents a high-risk, high-reward opportunity with strong revenue growth potential but faces challenges from negative net income and high debt levels. Key catalysts include continued earnings outperformance and AI platform adoption, while risks involve execution challenges and competitive pressures in the communications software sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →